Telix Pharmaceuticals Limited (TLX)
Telix Pharmaceuticals was planning to go public, but the IPO was withdrawn on Jun 14, 2024.
IPO Price
$11.87
Shares Offered
17,000,000
Deal Size
$201.79M
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of 576.27M AUD in the twelve months ending March 31, 2024. In the year 2023, Telix Pharmaceuticals had annual revenue of 502.55M AUD with 213.90% growth.
Revenue (ttm)
576.27M AUD
Revenue Growth
+213.90%
P/S Ratio
10.47
Revenue / Employee
1,388,602 AUD
Employees
415
Market Cap
4.05B undefined
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 502.55M | 342.45M | 213.90% |
| Dec 31, 2022 | 160.10M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTLX News
- 25 days ago - Telix Announces Launch of Proposed Initial Public Offering in the United States - GLOBE NEWSWIRE
- 6 weeks ago - Australian radiopharmaceutical biotech Telix Pharmaceuticals files for a $100 million US IPO - Renaissance Capital
- 6 weeks ago - Telix Files Registration Statement for Proposed Initial Public Offering in the United States - GLOBE NEWSWIRE
- 6 weeks ago - Telix Pharmaceuticals IPO Registration Document (F-1) - SEC